A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of Selonsertib in subjects with compensated cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

  • Hodge, Alex, (Primary Chief Investigator (PCI))

Project: Research

Project Description

NMA HREC Ref number: HREC/17/SVHM/11
NMA SSA Ref number: SsA/167/MonH246
Monash Health Ref: RES-17-0000-308X
SEO Code - 920106 Endocrine Organs and Diseases (excl. Diabetes)
StatusActive
Effective start/end date5/07/174/07/22